DDI Assessment
The mean concentration of 4β-HC showed no apparent increase after multiple doses of giredestrant for up to 84 days (cycle 4 day 1) at both the clinical dose (30 mg) and a supratherapeutic dose (90 mg; Change in 4β-HC concentrations over time, from baseline (cycle 1 day −7) to cycle 4 day 1When giredestrant 100 mg was coadministered with palbociclib 125 mg, giredestrant exposure was generally similar to that observed with single-agent giredestrant (